Research & Development
Alzheimer's: Page 5
Sysmex, Eisai tout Alzheimer's research at AD/PD 2022
As part of a nonexclusive agreement to create diagnostic agents for dementia, researchers from the companies compared the performance of the plasma beta-amyloid ratio measured using the Sysmex HISCL automated immunoassay system with that of amyloid status on positron emission tomography (PET) imaging as determined by the Centiloid method. Their technique was assessed in a discovery study in 180 patients and in a validation study involving 191 patients who were clinically diagnosed with mild Alzheimer's disease or mild cognitive impairment.
March 22, 2022
Spinal fluid tests may aid PET scans of Alzheimer's disease
A Swiss group led by senior author Michael Schöll, PhD, of the University Gothenburg investigated whether fluid and blood biomarkers that indicate Alzheimer's disease could predict the accumulation of neurofibrillary tau tangles seen on PET scans in patients diagnosed with the disease. They found the lab tests performed well enough to help select patients for PET imaging studies evaluating new treatments.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Brain surface renderings depict Pearson correlation coefficients adjusted for age and sex (r) representing the strength of the association between the different biomarkers and F-18 flortaucipir SUVR change in each brain region. The right upper panel represents age- and sex-adjusted Pearson correlation coefficients (r), along with p-values, for the association between the biomarkers and F-18 flortaucipir SUVR change in the Alzheimer's disease meta-region of interest (ROI). The root mean squared error (RMSE) for the prediction of F-18 flortaucipir SUVR change by a linear model with the biomarker as predictor and age and sex as covariates. RMSE was estimated using leave-one-out cross-validation. Voxel-wise statistical maps were thresholded using more lenient cluster-forming thresholds of p < 0.05 (uncorrected) at the voxel level and further thresholded at the cluster level by restricting results to clusters with a number of voxels higher than the expected number of voxels as predicted using random field theory. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
March 3, 2022
AltPep secures FDA breakthrough device designation
Soba-AD is designed to selectively detect toxic oligomers that trigger events associated with Alzheimer's disease such as cognitive impairment and neurodegeneration, according to the company. The goal is to detect the early molecular triggers of the disease before plaque formation, AltPep Founder and CEO Valerie Daggett, PhD, said.
March 1, 2022
Quanterix partners with Lilly on Alzheimer's diagnostics
Under the new partnership, Quanterix has received a nonexclusive, worldwide license to Eli Lilly's proprietary P-tau217 antibody technology. The company can utilize the blood-based biomarker for research use-only products and services, as well as future IVD applications.
March 1, 2022
Diadem wins CE-IVD Mark for Alzheimer's prognostic blood test
The prognostic blood test can predict likely progression to Alzheimer's disease up to six years in advance of symptoms, according to the company. AlzoSure previously received breakthrough device designation by the U.S. Food and Drug Administration (FDA) in January.
February 28, 2022
SDx partners with I-Ally on Alzheimer's test
The partnership's goal is to help caregivers get a diagnosis quickly for Alzheimer's disease in patients, as well as raising Alzheimer's awareness early in patients diagnosed with dementia.
February 24, 2022
Synaps Dx's Alzheimer's disease test gets payment code
The Discern test is the first autopsy-validated, minimally invasive test for the definitive diagnosis of Alzheimer's disease versus other forms of non-Alzheimer's disease dementias to earn PLA codes 206U and 207U, Synaps Dx said.
November 8, 2021
Diadem touts studies on Alzheimer's detection
AlzoSure is a plasma-based biomarker designed to predict the likelihood that a patient will develop Alzheimer's. Using patented technology, the assay employs an antibody that binds to a conformational variant of the p53 protein, U-p53AZ, which is a protein that plays a key role in AD progression.
February 2, 2021
Blood test shows promise in predicting course of Alzheimer's disease
A team led by Klaus Gerwert, PhD, and Julia Stockmann, PhD, both of the Bochum Research Center for Protein Diagnostics in Bochum, Germany, analyzed blood samples taken from 203 patients at the Alzheimer Center Amsterdam. The researchers used a test developed at Ruhr-Universität Bochum called the Immuno-Infrared Sensor, which identifies misfolding of the amyloid-beta peptide (a biomarker for Alzheimer's disease).
January 6, 2021
Tau Alzheimer's blood test gives PET a run for its money
The study of 490 people included healthy controls and participants with subjective cognitive decline or mild cognitive impairment who were tested for tau phosphorylated at threonine 217 (p-tau-217). Various methods of early detection of Alzheimer's were compared for their value in the detection of preclinical disease.
November 9, 2020
C2N Diagnostics debuts blood test to ID Alzheimer's disease
Samples from PrecivityAD are sent to the company's lab in St. Louis. Development of the test was supported by $2.8 million in funding from the Alzheimer's Drug Discovery Foundation over the past decade.
October 29, 2020
Tau blood test shows promise for very early Alzheimer's detection
One study was conducted at the lab of Dr. Randall Bateman, a Charles F. and Joanne Knight distinguished professor of neurology at Washington University in St. Louis. Researchers evaluated a mass spectrometry test for assessment of p-tau-217 and other tau fragments using small blood samples -- as small as 4 mL.
July 28, 2020
Page 5 of 7